Ovarian cancer begins in the ovaries or fallopian tubes and is often called the “silent killer” because early symptoms are subtle.
Globally, ovarian cancer is the seventh most common cancer in women, with over 300,000 new cases annually. Because early signs are easily missed, many patients are diagnosed at an advanced stage. However, timely intervention can still open a window for curative outcomes — so prompt medical evaluation is crucial.
China sees approximately 50,000 new cases of ovarian cancer each year, accounting for nearly 17% of the global burden. At Fosun Health, this substantial case volume gives our expert teams a depth of experience that ensures precision in every aspect of care — from accurate staging and individualized surgery to targeted therapy and long term survivorship management.
Every ovarian cancer program has surgery, chemotherapy, and targeted therapy. Here is what makes ours different:
"They said my cancer has spread throughout my abdomen. Is this the end?"
The challenge: Nearly 70% of ovarian cancers are diagnosed at Stage III or IV, with tumor nodules coating the peritoneum, omentum, and bowel surfaces. Patients are told "it's too late for surgery" or "we can only do palliative chemotherapy." But maximal tumor debulking—removing every visible cancer cell—directly determines survival. Achieving "R0" (no visible residual disease) can extend median survival from months to years.
Our answer: Maximal cytoreductive surgery (CRS) combined with HIPEC (Hyperthermic Intraperitoneal Chemotherapy).
- Robotic-Assisted Cytoreduction: The Da Vinci robot provides 10× magnified 3D vision and tremor-free instruments that navigate the complex abdominal cavity with sub-millimeter precision. We meticulously remove tumors from the ovaries, uterus, omentum, peritoneal surfaces, diaphragm, and involved bowel segments—while preserving uninvolved organs and critical structures. Even for extensive Stage IIIC disease, we aim for R0 resection.
- HIPEC: Immediately after surgery, we circulate heated chemotherapy (41–43°C) throughout the abdominal cavity for up to 90 minutes. The heat opens cancer cell membranes to allow deeper drug penetration, while the direct contact kills microscopic residual tumor cells that surgery cannot see. Studies show HIPEC after complete cytoreduction significantly extends progression-free and overall survival.
- Interval Debulking Strategy: For patients whose tumors are initially too widespread for safe primary surgery, we use neoadjuvant chemotherapy (NACT) to shrink the disease first—followed by interval cytoreduction with HIPEC. This converts "unresectable" to "optimally debulked."
What this means for you: Widespread peritoneal disease is not a death sentence. With maximal robotic cytoreduction plus heated intraperitoneal chemotherapy, even advanced-stage ovarian cancer can achieve long-term control—measured in years, not months.
"If you have to open my abdomen and remove everything, will I still feel like a woman? Will I ever recover?"
The challenge: Ovarian cancer surgery is among the most extensive in oncology: total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal stripping, and pelvic/para-aortic lymphadenectomy. The trauma is enormous. Younger patients lose fertility and ovarian hormone production overnight, plunging into surgical menopause. The recovery is long and painful. Many patients feel their womanhood has been taken along with their organs.
Our answer: Precision debulking with organ preservation where oncologically safe:
- Fertility-Sparing Surgery for Early Stage: For Stage IA/IC1 young patients with unilateral disease and favorable histology, we perform unilateral salpingo-oophorectomy with comprehensive surgical staging—preserving the uterus and contralateral ovary for future fertility. This is not "less treatment"; it is precision treatment tailored to biology.
- Nerve-Sparing Lymphadenectomy: The Da Vinci robot traces the pelvic autonomic nerves with sub-millimeter precision during lymph node dissection—preserving bladder function, bowel motility, and sexual sensation that traditional surgery often sacrifices.
- Ovarian Tissue Cryopreservation: For patients requiring bilateral oophorectomy who wish to preserve future hormonal potential, we offer preoperative ovarian tissue cryopreservation—a bridge to future fertility options.
- Minimally Invasive Approach: Where the disease burden permits, we perform laparoscopic or robotic staging and debulkingthrough small incisions—reducing postoperative pain, accelerating recovery, and allowing earlier initiation of chemotherapy.
What this means for you: "Maximal cytoreduction" does not mean "indiscriminate removal." We remove every cancer cell we can see—but we preserve every organ and every nerve that cancer has not touched. Your recovery, your hormone balance, and your sense of self matter as much as the surgery itself.
"My belly is so swollen I can barely breathe. I cannot eat, I cannot sleep, and the pain is unbearable. Can you help me first?"
The challenge: Advanced ovarian cancer fills the abdomen with malignant ascites—tens of liters of fluid compressing the lungs and diaphragm, causing breathlessness and agony. Tumor implants on the bowel surface cause malignant bowel obstruction—relentless vomiting, starvation, and dehydration. The pain from peritoneal carcinomatosis and nerve invasion can be opioid-resistant. Patients are too depleted to even consider chemotherapy.
Our answer: A multi-modal interventional rescue platform that restores comfort and function first:
- Ultrasound/CT-Guided Paracentesis with Intraperitoneal Therapy: We drain malignant ascites rapidly through a percutaneous catheter—relieving respiratory compression within hours. We then instill intraperitoneal chemotherapy or targeted agents directly into the abdominal cavity, achieving high local drug concentrations with minimal systemic toxicity. For recurrent ascites, we place a permanent tunneled catheter allowing home drainage.
- Self-Expanding Metal Stent (SEMS): For malignant small bowel or colonic obstruction caused by tumor implants, we deploy stents endoscopically or under fluoroscopy—reopening the digestive channel and restoring the ability to eat and drink.
- Celiac Plexus Blockade: For opioid-resistant upper abdominal and back pain from pancreatic/peritoneal nerve invasion, image-guided celiac plexus neurolysis interrupts the pain signaling pathway—often providing dramatic relief and reducing narcotic dependence.
- Tumor Hyperthermia: For peritoneal metastases and ascites, regional hyperthermia to 40–43°C sensitizes cancer cells to intraperitoneal chemotherapy—a force multiplier that makes the same drug dose more lethal to the tumor while sparing normal tissues.
What this means for you: Before we attack the cancer, we relieve the suffering. You will breathe comfortably again. You will eat again. The pain will be controlled. Only then—restored and strengthened—do you face definitive treatment.
"My cancer came back within six months of finishing chemotherapy. They say it is platinum-resistant. What is left for me?"
The challenge: Ovarian cancer follows a cruel pattern: most patients respond beautifully to first-line platinum-taxane chemotherapy, but recurrence is common. When the disease returns within six months, it is labeled "platinum-resistant"—and the treatment landscape narrows dramatically. PARP inhibitors, anti-angiogenic agents, and next-generation therapies exist, but they are expensive and not always available.
Our answer: In China, the next line is mapped to your tumor's biology—and it is accessible:
- PARP Inhibitors: For BRCA-mutated or HRD-positive ovarian cancer, olaparib, niraparib, and fluzoparib are approved and in routine use—delivering significant progression-free survival benefits as maintenance or treatment. For HRD-negative disease, PARP inhibitors still offer meaningful clinical benefit.
- Anti-Angiogenic Therapy: Bevacizumab combined with chemotherapy and as maintenance is approved for platinum-resistant and platinum-sensitive recurrent disease—starving the tumor by blocking new blood vessel formation.
- ADCs & Novel Targets: We provide access to FRα-targeted ADCs (mirvetuximab soravtansine) and other next-generation antibody-drug conjugates for folate receptor-alpha positive disease—offering new hope after multiple lines of therapy.
- Immunotherapy: For MSI-H/dMMR ovarian cancers, PD-1 inhibitors can induce deep and durable responses.
- Phase III Clinical Trial Fast-Track: When standard options are exhausted, we provide rapid access to trials of next-generation PARP inhibitors, dual angiogenesis-immunotherapy combinations, novel ADCs, and CAR-T cell therapy—typically 3–5 years ahead of availability elsewhere.
Because these therapies are developed and manufactured within China's ecosystem, comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US—with zero compromise in quality.
Guided by NGS-based BRCA/HRD testing and physicians who have sequenced thousands of ovarian cancer cases through multiple lines.
What this means for you: "Platinum-resistant" is a description of timing, not a terminal verdict. Your BRCA, HRD, or FRα status opens a direct path to targeted drugs that are available here, now, at a cost that makes long-term, multi-line treatment sustainable.
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs alongside your primary treatment as an "immune and vitality optimizer":
Toxicity Reduction: Herbal formulations help protect bone marrow function, ease chemotherapy-induced nausea and vomiting, reduce cancer-related fatigue, mitigate peripheral neuropathy from taxanes and platinum, and manage postoperative bowel dysfunction.
Efficacy Enhancement: Selected preparations may improve tumor sensitivity to chemotherapy and support recovery from extensive surgery.
Acupuncture provides additional support for pain, nausea, fatigue, and chemotherapy-induced neuropathy. The goal: reduce treatment burden, protect your immune function, and keep you strong enough to complete every planned cycle—and recover fully from surgery.
Every ovarian cancer case is reviewed by a panel comprising gynecologic oncology surgery, medical oncology, radiation oncology, interventional radiology, gastroenterology (for bowel involvement), clinical nutrition, radiology, and pathology specialists. Ovarian cancer decisions are uniquely complex: primary debulking versus interval debulking; HIPEC candidacy; fertility preservation feasibility in early-stage disease; and sequencing of PARP inhibitors, anti-angiogenics, and chemotherapy through lines of resistance.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your cancer stage, molecular profile (BRCA/HRD), surgical candidacy, nutritional status, and your priorities.
Diagnosis:
Stage IIIC Ovarian Cancer
Treatment Plan:
Neoadjuvant chemotherapy followed by Da Vinci robot-assisted interval cytoreductive surgery, hyperthermic intraperitoneal chemotherapy (HIPEC), and maintenance therapy with a PARP inhibitor. This strategy aimed to reduce tumor burden before interval debulking surgery and maximize long-term disease control.
Outcome:
Preoperative CT demonstrated significant reduction of the ovarian mass, marked decrease in ascites, and improvement of omental lesions. Serum CA-125 decreased to 184 U/mL.
The patient subsequently underwent Da Vinci robot-assisted interval cytoreductive surgery. The procedure was uneventful, and HIPEC was administered immediately afterward. Optimal cytoreduction was achieved, with no gross residual lesion greater than 1 cm remaining.
The patient was discharged 7 days after surgery and resumed normal activities within 5 weeks. Maintenance therapy with olaparib was planned for approximately 2 years. Follow-up CT at 18 months showed no evidence of recurrence, and CA-125 further declined to 18 U/mL.
The patient returned to part-time work, remained fully independent in daily living, and maintained regular walking and low-intensity exercise.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your transvaginal ultrasound images, CT/MRI scans, CA125/HE4 levels, pathology reports, and NGS results (BRCA, HRD, HER2, MSI). Our multidisciplinary ovarian cancer team will provide a personalized treatment plan—including fertility preservation assessment and interventional downstaging strategy—within 48 hours.
